Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
Resistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence...
Full description
Bibliographic Details
| Main Authors: |
Nindo B. Punturi,
Sinem Seker,
Vaishnavi Devarakonda,
Aloran Mazumder,
Rashi Kalra,
Ching Hui Chen,
Shunqiang Li,
Tina Primeau,
Matthew J. Ellis,
Shyam M. Kavuri,
Svasti Haricharan |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Publishing Group
2021-05-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-021-23271-0
|
|---|
